Login to Your Account

4SC, Leo Pharma Ink $125M Preclinical Deal in Psoriasis

By Cormac Sheridan
Staff Writer

Tuesday, February 26, 2013
4SC AG could earn up to €96 million (US$125 million) in option and milestone payments arising out of a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S, as well as double-digit royalties on eventual product sales. 4SC is getting a €1 million option fee up front and would receive another €3 million should Leo, of Ballerup, Denmark, exercise its option.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription